HIV Prevention
Conditions
Keywords
HIV, prevention
Brief summary
The purpose of this trial is to assess the safety and acceptability of Tenofovir (TFV) 1% gel in adolescent females over 12 weeks of a minimum of twice weekly dosing following the BAT24 regimen.
Interventions
DRUGTFV 1% vaginal gel
Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
DRUGHEC Placebo Gel
Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
Sponsors
CONRAD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
15 Years to 17 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 15 through 17 years, inclusive, as per site policy * General good health (by volunteer history and per investigator discretion) without any clinically significant systemic disease (including, but not limited to significant liver disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis or bone disease, and diabetes) * Able to communicate in spoken and written English * Willing to following instructions regarding vaginal activity and vaginal products as follows: 1. Willing to abstain from all vaginal activity, including intercourse, for 48 hours prior to Visit 2 and 48 hours prior to Visit 7 2. Willing to abstain from the use of vaginal products other than the study product including spermicides, lubricants, and douches for the duration of study participation. Note: Tampons may be used for menses, but pads should be used for any other intermenstrual spotting or bleeding. * Assessment of onset and progression of puberty as measured by Tanner Stage 4 or 5 * History of consensual penile-vaginal intercourse (at least one episode in participant's lifetime) * Negative urine pregnancy test * Use of an effective method of contraception for at least the past 30 days (per participant report) and intended use for the duration of study participation. Effective methods include: 1. Hormonal methods (excluding contraceptive ring) 2. Intrauterine contraception (IUC) Note: An IUC must be in place for at least 15 days prior to enrollment * Willing to give voluntary assent, and comply with study procedures as required by the protocol assent and willing for parent/guardian to provide written informed consent for participation as per Institutional Review Board (IRB) requirements. Emancipated minors may give their own informed consent.
Exclusion criteria
* Known adverse reaction to study products (ever) or latex, per participant report * Non-therapeutic injection drug use in the last 12 calendar months * Post-exposure prophylaxis (PEP) for HIV-1 exposure within the last 6 calendar months * Currently pregnant or within 30 days from the last pregnancy outcome. Note: If recently pregnant must have had at least two spontaneous menses since pregnancy outcome. * History of gynecological procedures (including genital piercing) on the external genitalia, vagina or cervix within the last 14 days * Intention to become pregnant in the next 6 months * Currently breastfeeding or having breastfed an infant in the last two months, or planning to breastfeed during the course of the study * Positive for HIV * Grade 2 or higher as per the Division of AIDS (DAIDS) Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009) of the following: 1. Alanine transaminase (ALT), aspartate aminotransferase (AST) 2. Creatinine 3. Hemoglobin 4. Platelet count 5. Hepatitis B surface antigen (HBsAg) Note: Otherwise eligible participants with an exclusionary test result(s) listed above may be re-tested a maximum of one time and if a non-exclusionary result is documented within the 30 days of providing informed consent, they may be enrolled. * Clinically apparent Grade 2 or higher pelvic examination finding (observed by study staff) per the Female Genital Grading Table for Use in Microbicide Studies (Addendum 1 to the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009) Note: 1) Cervical bleeding associated with speculum insertion and/or specimen collection judged to be within the range of normal according to the clinical judgment of the Principal Investigator/designee is considered expected non-menstrual bleeding and is not exclusionary. 2) Otherwise eligible participants with exclusionary pelvic examination findings may be enrolled /randomized if improvement of findings to a non-exclusionary grade or to resolution can be documented within 30 days of providing informed consent for Screening. * Current pelvic inflammatory disease (PID) or sexually transmitted infection requiring treatment per current Centers for Disease Control and Prevention (CDC) guidelines (e.g., Trichomonas vaginalis, Neisseria gonorrhea (GC), Chlamydia trachomatis (CT), or active herpes outbreak) * Symptomatic vulvovaginal candidiasis, symptomatic bacterial vaginosis (BV) or urinary tract infection (UTI) Note: Otherwise eligible participants with symptomatic vulvovaginal candidiasis, BV or UTI prior to genital sampling at Visit 2 will be offered treatment and may be continue in the study after completing treatment and all symptoms and findings have resolved. * Systemic use in the last two weeks or anticipated use during the study of any of the following: corticosteroids, antibiotics, antifungals, antivirals (e.g., acyclovir or valacyclovir) or antiretrovirals (e.g., Viread®, Atripla®, Emtriva®, Complera®, Stribild®). Note: Participants should avoid non-steroidal anti-inflammatory drugs (NSAIDs) except for treatment of dysmenorrhea during menses. Participants may use Tylenol® on an as-needed but not daily basis during the study. * Participation in any other investigational trial (device, drug, or vaginal trial) within the last 30 days or planned participation in any other investigational trial during the study * Any other condition that, in the opinion of the Principal Investigator (PI) or designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in genitourinary adverse events (AEs) | 24 hours after single dose; 1, 2, 4, 8 and 12 weeks during/after repeat dosing | Number of genitourinary adverse events (AEs) |
| Changes in soluble markers of inflammation in cervicovaginal fluid (CVF) | Baseline; 24 hours after single dose; 12 weeks after repeat dosing | changes in soluble markers of inflammation in cervicovaginal fluid (CVF) |
| Changes in vaginal microflora as assessed by Gram stain and semi-quantitative vaginal culture | Baseline and 12 weeks after repeat dosing | Changes in vaginal microflora as assessed by Gram stain and semi-quantitative vaginal culture |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anti-HIV and anti-herpes simplex virus (HSV)-2 activity in the CVF | Baseline; 24 hours after single-dose; 12 weeks after repeat dosing | Anti-HIV and anti-HSV-2 activity in the CVF |
| Responses to key questions on acceptability questionnaire | 2, 8 and 12 weeks during/after repeat dosing | Responses to key questions on acceptability questionnaire |
| Biologic markers of adherence via returned empty applicators | 2, 4, 8 and 12 weeks during/after repeat dosing | Biologic markers of adherence via returned empty applicators |
| Real time adherence via internet-based diary | 12 weeks | Real time adherence via internet-based diary |
| TFV concentration in plasma | 2 and 24 hours after single dose | TFV concentration in plasma |
| TFV concentration in CVF | 24 hours after single does; 2, 4, 8, and 12 weeks during/after repeat dosing | TFV concentration in CVF |
Countries
United States
Outcome results
None listed